M. S. De Propris

Early clearance of hairy cell leukaemia in the bone marrow after first‐line treatment with cladribine predicts a favourable outcome

Silvio Ligia, Mauro Passucci, Giovanni Manfredi Assanto, G. M. D'Elia et autres

First-line purine nucleoside analogues (PNAs) in hairy cell leukaemia (HCL) allow deep and long-lasting responses. We retrospectively analysed 53 HCL patients treated frontline with cladribine and assessed for response at 2 and 6 months after treatment to evaluate the kinetics of response. …

it (code pays fourni par la source)

P04 MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Francesca Fazio, Gianfranco Lapietra, Marco Limongi, Stefania Intoppa et autres

The European Myeloma Network has underlined the clinical utility of multiparametric flow-cytometry (MFC) analysis in the work-up and follow-up of multiple myeloma (MM) patients. The prerequisite of MFC in MM is to discriminate within the whole PC compartment between normal and aberrant …

it (code pays fourni par la source)

S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS.

Renato Bassan, Sabina Chiaretti, Irene Della Starza, Orietta Spinelli et autres

Background: Pediatric-inspired chemotherapy is standard of care for younger adults with Ph− ALL/LL. An essential component of these regimens is pegaspargase, here incorporated into a national treatment program for patients 18-65 years. Aims: To assess in the GIMEMA Phase 2 LAL 1913 …

it (code pays fourni par la source)

P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL

Sabina Chiaretti, Renato Bassan, A Vitale, L Elia et autres

Background: The outcome of adult Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) patients greatly improved since the introduction of tyrosine kinase inhibitors (TKIs). A further improvement was achieved with a chemo-free induction/consolidation strategy based on the sequential administration of dasatinib followed by blinatumomab …

it, us (code pays fourni par la source)

P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY

Alessandro Natoni, Marina Cerreto, M. S. De Propris, Martina Petrucci et autres

Background: Multiple myeloma (MM) is a plasma cell disorder that develops in the bone marrow (BM), characterized by an unchecked proliferation and by the ability to disseminate in different parts of the skeleton. Several studies have highlighted a prominent role of platelets …

it, ie (code pays fourni par la source)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances

Irene Della Starza, Sabina Chiaretti, M. S. De Propris, Loredana Elia et autres

Introduction. Acute lymphoblastic leukemia (ALL) is the first neoplasm where the assessment of early response to therapy by minimal residual disease (MRD) monitoring has proven to be a fundamental tool to guide therapeutic choices. The most standardized methods to study MRD in …

it (code pays fourni par la source)

PF375 IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY

Francesca Romana Mauro, Stefano Molica, Francesca Paoloni, Gianluigi Reda et autres

Background: Single agent Ibrutinib (IBR), an inhibitor of Bruton's tyrosine kinase, is approved for the front-line treatment of patients with chronic lymphocytic leukemia (CLL). Aims: As in CLL patients, the addition of anti-CD20 monoclonal antibody provides superior efficacy to chemotherapy, in a …

it, jp (code pays fourni par la source)

PF359 TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IBRUTINIB TREATMENT

Luciana Cafforio, Luca Vincenzo Cappelli, Ilaria Del Giudice, Caterina Ilari et autres

Background: Ibrutinib (IBR) is active in chronic lymphocytic leukemia (CLL) patients (pts) with TP53 aberrations. Aims: To investigate the dynamics of TP53 mutations (TP53‐mut) in treatment‐naïve and relapsed CLL pts treated with IBR. Methods: Fifty‐four pts (33 unmutated, 21 mutated IGHV; 7/50 …

it (code pays fourni par la source)

Clinical relevance of silent red blood cell autoantibodies

Francesca Romana Mauro, Fabio Trastulli, Cristiano Alessandri, Guido Valesini et autres

..

it (code pays fourni par la source)

Spontaneous Clinical Regression In Chronic Lymphocytic Leukemia : Clinical And Biologic Features Of 9 Cases From The ERIC Registry

Ilaria Del Giudice, Andrea Visentin, Livio Trentin, Max Flogegård et autres

Spontaneous Clinical Regression In Chronic Lymphocytic Leukemia : Clinical And Biologic Features Of 9 Cases From The ERIC Registry

Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial

Francesca Romana Mauro, Angelo Michele Carella, Stefano Molica, Francesca Paoloni et autres

The activity and safety of a regimen combining lenalidomide with fludarabine and cyclophosphamide (FC) was investigated in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Treatment consisted of six monthly courses of the FC regimen combined with 14 days of lenalidomide given …

it (code pays fourni par la source)

RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications

Valentina Gianfelici, Sabina Chiaretti, Sofie Demeyer, Filomena Di Giacomo et autres

Despite therapeutic improvements, a sizable number of patients with T-cell acute lymphoblastic leukemia still have a poor outcome. To unravel the genomic background associated with refractoriness, we evaluated the transcriptome of 19 cases of refractory/early relapsed T-cell acute lymphoblastic leukemia (discovery cohort) …

it, be, us (code pays fourni par la source)